Utility of Potent Anti-viral MicroRNAs in Emerging Infectious Diseases by Golkar, Zhabiz et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 16
Utility of Potent Anti-viral MicroRNAs in Emerging
Infectious Diseases
Zhabiz Golkar, Donald G. Pace and Omar Bagasra
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61687
Abstract
MicroRNAs (miRNAs) are small, noncoding RNA molecules that have emerged as im‐
portant posttranscriptional regulators of gene expression. miRNA provides intracellular
immune defense when the body is faced with challenges from transgenes, viruses, trans‐
posons, and aberrant mRNAs. miRNA molecules trigger gene silencing in eukaryotic
cells. To date, more than 3,000 different human miRNAs (hsa-miRs) have been identified,
and it is generally agreed that cellular gene regulation is significantly impacted by the
presence of miRNAs. A single miRNA has the complex capacity to target multiple genes
simultaneously. In a viral infection context, miRNAs have been connected with the inter‐
play between host and pathogen, and occupy a major role in the host–parasite interaction
and pathogenesis. While numerous viral miRNAs from DNA viruses have been identi‐
fied, characterization of functional RNA virus-encoded miRNAs and their potential tar‐
gets is still ongoing. Here, we describe an in silico approach to analyze the most recent
Ebola virus (EBOV) genome sequences causing West African epidemics. We identified
numerous “candidate” miRNAs that can be utilized to quell the Ebola virus. Future ap‐
proaches will focus on experimental validation of these miRNAs during quelling the Ebo‐
la target transcripts for further elucidating their biological functions in primates and
other animal models.
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1. Introduction
1.1. Inhibition of Ebola virus by anti-Ebola miRNAs In silico
Since the HIV-1 pandemic of the 1980s and more recent outbreaks of bird flu, severe acute
respiratory syndrome (SARS), and Middle East respiratory syndrome-Corona Virus (MER-
CoV), it has been widely believed that there would be new pandemics of highly pathogenic
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viruses [1]. Fortunately, until recently, many of the new emerging pathogenic agents, such as
Ebola virus (EBOV) and Marburg virus (MARV), have failed to demonstrate the transmissi‐
bility or animal reservoirs required to become true pandemic threats [2, 3]. Few, if any,
antivirals can claim to be specific enough to halt the epidemic. Recently, a whole EBOV
replication-defective vaccine—EBOVdVP30—has been found to be very effective in nonhu‐
man primates, while two others are in Phase II trials [4].
The testing of the recently developed replication-defective recombinant chimpanzee adeno‐
virus type 3–vectored ebolavirus (cAd3-EBO) vaccine is based on a demonstration of efficacy
in a nonhuman primate model [5]. However, a curious finding has puzzled the investigators
—preexisting neutralizing antibodies against cAd6 and cAd68 in human serum samples were
found in ~40% of Ugandans and in 15% of the US and European volunteers. The increased
prevalence of neutralizing antibodies against chimpanzee adenoviruses in sub-Saharan Africa
may indicate cross-species transmission of these viruses from chimpanzees to humans. The
possibility of fairly high levels of neutralizing antibodies against cAd3 may complicate the
evaluation of the effectiveness of Ebola vaccines currently underway.
1.2. Virology of Ebola virus
Filoviruses are taxonomically classified within the order Mononegavirales, a large group of
enveloped viruses whose genomes are composed of a nonsegmented, single-stranded minus
[2, 3] RNA molecule. Following their discovery, filoviruses were originally grouped with
rhabdoviruses, as the appearance of these virus particles appeared similar [3]. However,
subsequent filamentous morphology and extensive genetic, physiochemical, and virologic
studies of Marburg virus (MARV) and Ebola virus (EBOV) revealed distinctive characteristics,
and these viruses were placed into a separate family, the Filoviridae [3]. Further characterization
of these agents demonstrated that EBOV and MARV represent divergent lineages of filovi‐
ruses, and that their variances were significant enough to warrant the formation of the two
genera, MARV and EBOV [4]. Subsequent to the International Committee on Taxonomy of
Viruses recommendation, the MARV genus contains a single species, the Lake Victoria
Marburg virus, as this strain exhibits only limited genetic variation.
EBOV is the causative agent of Ebola virus disease (EVD) [6]. The mortality rate can vary from
40% to 93% depending on the strains [6]. The viral life cycle begins with host cell entry through
a mechanism that is still poorly understood. The incubation period for EVD is 2–21 days, and
typical early symptoms include fever, chills, malaise, and myalgia (all of which could be
misdiagnosed as malaria, which is highly prevalent in West African nations), followed by the
onset of symptoms indicative of multi-organ stress and subsequent failure, sometimes
followed by hemorrhagic episodes that can easily be misdiagnosed as Lassa fever.
EBOV is a negative, single-stranded RNA virus with an unusual, variable-length, filamentous,
branched morphology whose helical capsid is enclosed inside a membrane. The mechanism
of attachment and entry into the cell is still not completely defined (see discussion below).
Once inside, the viral RNA polymerase (L protein) begins to copy the negative strand (–ve)
RNA to make the positive strand (+ve) transcripts that mimic the structure of mRNA and are
translated by host ribosomes. Replication is thought to occur in the cytoplasm. An unusual
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feature of the transcription and translation of the Ebola genes is the fact that the glycoproteins
(GP) are only expressed through transcriptional editing. The genome of the Zaire Ebola virus
(EBOV), the most pathogenic among all species of EBOV, is 18,959 nucleotides (nts) in length
and contains seven transcriptional units that guide synthesis of at least nine distinct primary
translation products: the nucleoprotein (NP), virion protein (VP) 35, VP40, glycoprotein (GP),
soluble glycoprotein (sGP), small soluble glycoprotein (ssGP), VP30, VP24, and the large (L)
protein. L is the catalytic subunit of the viral polymerase complex (Figure 1). Similar to other
nonsegmented negative-sense (NNS) RNA viruses, EBOVs encode a multiprotein complex to
carry out replication and transcription. In the case of EBOV, viral RNA synthesis requires the
viral NP, VP35, VP30, and L proteins. Transcription of filovirus mRNAs is presumed to occur
as in other NNS viruses, where there is a gradient of viral mRNAs with the abundance of each
mRNA transcript decreasing as the polymerase transcribes toward the 5′ end of the template
[7]. Each EBOV mRNA is presumed to be efficiently modified with a 5′–7’-methylguanosine
(m7G) cap and a 3′p (A) tail [8].
Figure 1. The genome of EBOV, 18 9 kb in length, has the following gene order: 3′ leader nucleoprotein (NP), virion
proteins (VP) VP35-VP40, membrane glycoprotein (GP), viral polymerase (VP) VP30-VP24, viral polymerase L protein,
and 5′ trailer.
The Ebola virus genus possesses greater diversity, and four viral species have been recognized:
Zaire Ebola, Sudan Ebola, Reston Ebola, and Ivory Coast Ebola (EBOV-Z, EBOV-S, EBOV-R,
and EBOV-IC, respectively). Each of the EBOV species has a different degree of pathogenicity
and mortality rate [9]. Therefore, EBOV-S and EBOV-Z, which are the predominant EBOVs
associated with known outbreaks, are more pathogenic than EBOV-R and EBOV-IC [10].
EBOV-IC has only caused a single nonfatal human infection, but EBOV-R has caused fatal
infection in nonhuman primates [8]. However, EBOV-S, EBOV-Z, and EBOV-B often cause
severe hemorrhagic diseases with markedly high case fatality rates (40–90%) [10]. The EBOV
genome is 18.9 kb in length with the following gene order: 3′ leader nucleoprotein (NP), virion
protein (VP) 35-VP40, glycoprotein (GP), VP30, VP24, polymerase (L), and 5′ trailer. The GP
differences between any two species range from 37% to 41% at the nucleotide level and from
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34% to 43% at the amino acid level [40]. However, variations within EBOV-Z species are very
low (∼2–3%) [11]. Thus, GP nucleotides are usually used in the phylogenetic analysis of EBOV
(Figure 2).
Figure 2. The Ebola Pandemic Map depicts the history of Ebola in Africa. The sporadic cases of Ebola were common in
the central African countries such as the DRC (988 cases with 767 fatalities), Uganda (606 cases with 283 fatalities),
South Sudan (335 cases with 180 fatalities), Gabon (214 cases with 150 fatalities), the Republic of the Congo (248 cases
with 210 fatalities), and South Africa (2 cases with 1 fatality).
Because of their high mortality rate, which can vary from 40% to 93%, and their potential
for  person-to-person transmission and lack of  an approved vaccine or  antiviral  therapy,
MARV  and  EBOV  are  classified  as  biosafety  level  4  (BSL-4)  viruses  by  World  Health
Organization [12, 13]
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1.3. History of MARV and EBOV
Viruses are obligate intracellular parasites and essentially rely on host cells for raw materials,
replication, transcription, and translations of their genetic codes. Until a few years ago, we
assumed that the major intracellular defenses against viral pathogens were interferons [13].
Since the discovery of RNA interference (RNAi) and miRNAs, we know that one of the
fundamental functions of miRNAs is to prevent replication of foreign viruses by pre- and
posttranscriptions and suppressions of viral expression [12]. Therefore, besides endogenous
gene regulation, miRNAs are the primary intracellular immune defense system [13]. Viruses
have also evolved to counter the antiviral effects of miRNAs by viral miRNAs (vmiRNAs).
Recently, Li and Chen [14] have conducted molecular epidemiologic analyses of presently
extant  Ebola viral  genomes to ascertain their  evolutionary viral  history.  Of  considerable
potential importance are interpretations derived from a dataset that is between 1,000 and
2,100 years old and includes four Ebola species (EBOV-Z, EBOV-S, EBOV-TF, EBOV-R) [15].
Logically, one could assume that over the past 2,000 years, humans have evolved counter‐
measures  to  the  Ebola  virus  via  innate,  adaptive,  and  miRNA-based  immunity.  The
identification in a  human database of  71 miRNAs capable of  potentially quelling EBOV
strongly suggests that Homo sapiens  already have developed primary intracellular defens‐
es to quell EBOV infection [16]. This raises a question: Why have EBOVs been circulating
for about 2,000 years, and yet they seem to have emerged only recently? The earliest known
cases of Ebola date to the 1970s. One theory proposes that EBOV-Z experienced a recent
genetic bottleneck [17].  Before Ebola viral  strains were introduced to primates,  they had
already  been  circulating  among  small  mammals,  including  bats,  rodents,  marsupials,
shrews, and so on [16]. Although these bats and other animals were infected [15, 16], no
evidence demonstrated that such infections were fatal to them [18]. This indicates that a
natural  balance  had  been  achieved  between  the  viruses’  pathogenicity  and  the  host’s
immune system, especially at the intracellular levels where miRNAs provide immunologi‐
cal protection [19].  This homeostasis,  this balance, apparently was broken in 1900, when
EBOV genetic diversity experienced a dramatic drop [16].  Accordingly,  most lineages of
the various EBOV species became extinct because of such influences as threatening human
activities,  climate  change,  and  a  steep  decline  in  the  number  of  animals  to  serve  as  a
reservoir for viral replication. Probably due to altered patterns of positive selection in the
glycoprotein (GP), which diversified substantially and was found to be part of fusion and
receptor  binding  within  cellular  membranes,  infection  patterns  through  direct  exposure
were changing. Therefore, by about 1970, few lineages that possessed broader tropism and
enhanced  fitness  had  the  capacity  to  infect  primates  via  direct  exposure  [16].  Similar
examples can be seen in the emergence of HIV-1, which appeared to have surfaced in the
1950s through a zoonotic event that involved common infections among chimpanzees (i.e.,
SIV) and then accidentally jumped to humans [16–18].  Due to the paucity of  significant
differences in EBOV genetic diversity since 1970, the decreased number of surviving viruses
may have become the only circulating lineages in primates and viral reservoirs. EBOV-Z
has the ability to traverse a long distance through bats, which serve as a migratory reservoir.
Outbreaks with their epicenter in Congo have been caused by the EBOV-Z species [20–23].
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Through analysis of miRNA numbers that demonstrate high homologies in seed sequences
and that show high identity to EBOV species, we have deduced that the genetic variations at
the GP may serve as a type of Achilles’ heel. After all, only one miRNA showed identity to GP,
while eight proved capable of blocking polymerase steps. This indicates that minor variations
within the GP amino acid sequence could allow for viral entrance into host target cells in
humans. The subsequent transcription of negative-stranded RNA viruses into positive RNA
strands occurs amid a struggle to overcome the miRNAs with quelling potential that can halt
this process. It is possible that at the time of exposure to EBOV, all of the protective miRNAs
may not be present in the target cells, or may be present, but not in sufficient quantities to block
early EBOV replication [24].
Figure 3. The illustration depicts a simplified structure of Ebola virus. The functions of various viral proteins are de‐
scribed in the text. GP, glycoprotein; NP, nucleoprotein; VP40, matrix protein; VP30, transcription factor; and polymer‐
ase enzyme.
Figure 3 shows the VP24, VP30, VP35, VP40, and L nucleoproteins that constitute the nucleo‐
capsid, which is crucial in both the transcription and viral replication processes [25, 26]. The
glycoprotein is located in the lipid membrane of the Ebola virus; this is also the place in the
host target cells where receptors that facilitate viral entry are embedded [27]. Viral matrix
proteins VP40 and VP24 are essential to viral budding, stability, and structure. VP40 is the
primary matrix protein, and is the viral protein that is expressed most abundantly. It plays a
central role in the process of Ebola budding from the plasma membrane. For example, in
mammalian cells, the mere expression of VP40 is sufficient to create virus-like particles (VLPs)
with morphological characteristics that are similar to those of the actual Ebola virus [28, 29].
Given VP40’s absence, studies have found that the nucleocapsid was not transported effec‐
tively into the plasma membrane, and as this membrane is the site of assembly, budding, and
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incorporation into the virions, considerable attention should be given to the role of this matrix
protein [30]. The utilization of miRNAs that specifically target VP40 mRNA degradation is
important to our understanding of just how VP40 functions and what potential roles it might
play in the regulation of VLP assembly in both in vitro and live cell settings. hsa-miR-4692 and
hsa-miR-548-az effectively target VP40; therefore, the overexpression of these particular
miRNAs within host cells could totally disrupt the viral life cycle and may have a decisive
impact in the categorization of therapeutic targets (data unpublished). The tendency of Ebola
VP40 to assemble virus-like particles (VLPs) presents an appealing model for analysis of the
Ebola viral assembly at biosafety level 2 made possible by the noninfectious nature of geneti‐
cally engineered VLPs [31].
VP40’s association with the plasma membrane is of fundamental importance [30]; it is here
that assembly is initiated as well as oligomerization [31], and nucleoprotein recruitment.
Besides membrane association, VP40 also associates or otherwise interacts with host cell
factors, including the endosomal sorting complex that supports transport (ESCRT) machinery
[27, 29], the vesicle coat II proteins (COPII) [24], as well as the protein actin [25, 30]; these host
cell factors, respectively, have been shown to enable VP40 budding, transport, and movement.
Moreover, host cell protein kinases could contribute to Ebola infectivity as c-Abl1 can phos‐
phorylate Tyr13 in VP40 [32, 33]. Still we have an inadequate understanding of how VP40
actually assembles on the plasma membrane before virion release occurs. Localization of VP40
in the plasma membrane is believed to be important as studies give evidence that hydrophobic
residues located within the C-terminal domain, including Leu213, are essential in the localiza‐
tion and budding processes [32]. Detection of VP40 oligomers in VLPs and UV-inactivated
virions has occurred [34, 35]; they have been detected mainly in filamentous structures
stemming from the plasma membrane [36]. Therefore, VP40 oligomerization apparently occurs
on the same plasma membrane in which oligomers selectively have found to reside [37]. In
terms of structure, VP40 has predominantly been found to oligomerize into either hexamers
or octamers [38, 39]. These share a comparable monomer–monomer (or intradimeric) antipar‐
allel interface. However, the detection of oligomeric structures in live cells suggests that these
structures, too, could exert a critical influence on both viral assembly and egress [40]. We
discovered that hsa-miR-4692 and hsa-miR-548-az both target VP40 (data unpublished).
The formation of virus-like particles (VLPs) requires VP40 oligomers; these are associated with
membranes that are resistant to detergent [41], which underscores the active part that the
plasma membrane may play in VP40 oligomerization. Moreover, on the plasma membrane,
matrix protein oligomerization may function as a scaffold in host protein recruitment, and also
supply the force needed to effect the formation of virus particles and the deformation of
membranes. A comprehension of VP40 plasma membrane association thus becomes crucial to
our understanding of how the formation of protein buds occurs on the plasma membrane.
Gupta K [42] recently investigated the role that the VP40 C-terminal domain plays in mem‐
brane association as well as in membrane penetration. These investigators utilized the
monolayer penetration methodology to conduct in vitro research into the molecular basis of
the penetration of the VP40 membrane. To study VP40 assembly and its associated egress in
cells, they employed a multipronged methodology that blended cellular imaging, number and
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brightness (N&B) analysis, analysis of the egress of virus-like particles, site-directed muta‐
genesis, and total internal reflection (TIRF) microscopy. N&B analysis permitted them to
ascertain the average number of molecules and also the brightness within each pixel within a
fluorescence microscopy image. This permitted them to detect the oligomeric status of proteins
that are labeled fluorescently. They concluded that within the VP40 C-terminal domain, a
hydrophobic interface actually penetrates the plasma membrane, which plays a key role in the
oligomerization of VP40. The knocking out of plasma membrane penetration by hydrophobic
mutants also substantially reduces the egress of VLPs [38, 39]. Therefore, degradation of VP40
mRNA by a two-pronged attack from hsa-miR-4692 and hsa-miR-548-az can stop Ebola.
A distinguishing characteristic of filovirus genomes is their 3′- and 5′-UTRs that are long
related to other RNA viruses of the nonsegmented negative-strand (NNS) variety [40]. Of
particular note, Kochetov AV [41] concentrated on the 5′-UTRs in the mRNA of seven EBOV
viruses, due to the critical importance of the 5′-UTRs in translation initiation. In four of these
seven mRNAs, small alternate upstream open reading frames (uORFs) were identified, but
their significance is yet to be fully characterized. In cellular mRNAs, uORFs are known to be
a common feature; they are critical in modulating translation of primary ORFs (pORFs), which
was accomplish by reducing the efficiency and quantity of the scanning ribosomes associated
with the reinitiation that occurs at the start codon of pORFs [42]. At a uAUG, rather than a
pAUG, translation initiation frequency is affected by a variety of factors, including the strength
of the Kozak consensus sequence that surrounds the uAUG. Moreover, between the pAUG
and the upstream open reading frame (uORF) is an intercistronic space that, combined with
the phosphorylation status of and the eIF-2α [43, 44], controls whether translation takes place
at the principal protein initiation site (pAUG) or at the termination codon (uAUG).
When eIF-2α∼P is absent, cap-dependent translation has been found to be efficient, which
permits higher ribosome initiation rates at the uORF [45]. When eIF2α∼P is enhanced,
impairment of translation initiation occurs, which causes a ribosome to continue scanning
beyond the uAUG; in this case, initiation occurs at the pAUG. In short, when cell stress occurs,
eIF2α∼P facilitates translation initiation of select mRNAs that possess uORFs at the primary
open ready frame (pORF) [46].
They characterized how the EBOV 5′-UTRs modulate translation. Mutating any of the four
uAUGs present in the EBOV genome enhances translation at the corresponding pORF. The
most dramatic effect was with the L gene where the L uAUG can potently suppress pORF
translation; however, in response to eIF2α∼P, the L uAUG maintains L translation. Modulat‐
ing viral polymerase levels is biologically significant as ablating the L uORF in a recombinant
EBOV reduces viral titers 10- to 100-fold in cell culture, severely impairs viral RNA synthesis,
and functions to maintain virus titers in cells treated with stress-inducing agents. These data
suggest that a uORF in the EBOV L mRNA regulates polymerase expression in response to the
status of the cellular innate immune response and is required for optimal virus replication.
It would be relatively easy to incorporate a combination of relevant miRNAs in a miRNA-
expression vector to test the utility of these miRNAs in genetically engineered VLP cell models
in vitro that can be performed in a BSL-2 facility, and then to extend these studies in animal
models utilizing safe vectors in a BSL-4 environment.
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Currently,  there are several  genetically engineered vaccines containing genes for surface
proteins (GP) that  are in clinical  trial.  The first  among these is  a  vaccine that  Ebola GP
genes stitched into a weakened chimpanzee adenovirus that serves as a vector. The second
vaccine  contains  the  Ebola  surface  protein  gene  inside  a  weakened version of  vesicular
stomatitis  virus  (VSV),  which commonly infects  farm animals.  The potential  dangers  of
employing of  VSV are  obvious:  it  can save men but  potentially  harm livestock in West
Africa. The chimpanzee adenovirus will be a zoonotic event itself, and its potential danger
cannot be underestimated [47, 48].
The third vaccine uses a vector known as MVA, a modified version of the smallpox vaccine
virus, and involves protection from an Ebola virus “challenge” 10 months after the last
vaccination.
We noted that none of these three approaches mentioned a simple and well-tested method
of human and animal vaccination. What happened to the simple, whole formalin-killed or
UV-killed, less pathogenic EBOV vaccines that have been tried in so many viral vaccina‐
tions [49, 50]?
With viruses like the major Ebola strands, where the mortality rate is over 50%, it will be
difficult to find a reasonable and ethical way to carry out an unbiased clinical trial. However,
if one can prepare a “dead Ebola virus” with antigenicity intact, it would be easy to immunize
“high risk groups” without utilizing unusual vectors as exemplified by “harmless” chimpan‐
zee adenovirus, VSV or MVA (modified smallpox virus), each with unknown long-term risk
factors and accompanied by immediate concerns of viral vector-induced antigenic competition
that may potentially quell proper immune responses to the Ebola antigens [51]. We believe
that a dead vaccine may induce the protective miRNAs and quell the pandemic. Increasingly,
miRNA-induced intracellular immunity is being better understood, and several clinical trials
are under way to treat viral diseases and cancers [52–55]. The cost of each of these vaccines
would run into millions of dollars and would be prohibitively expensive to any of the
individuals who are predicted to be infected with the virus in West African nations. In contrast
to the proposed recombinant vaccines, each of the more traditional “killed vaccines” has been
very inexpensive to produce and has benefited billions of humans [56].
2. Conclusions
The current ongoing Ebola outbreaks in West Africa that began almost three years ago in March
2013 have already claimed 11,000 lives and over 27,000 cases. The rapid spread of the infection
demands the need for rapid prevention methods. Currently, there are several vaccines that are
in different phases of clinical trials. In this report, we highlight an alternative to the standard
vaccine for Ebola prevention. We show that a preventive method based on miRNAs could be
utilized and tested in nonhuman primates. Some of the lessons that we have learned from the
recent West Africa Ebola outbreaks is to test the vaccine and other preventive methods that
are currently available against Ebola before the major outbreaks occur. Therefore, we recom‐
mend that vaccines and preventive methods must be developed to the point that the measures
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correlate for human protection (Phase I level), so when the outbreaks occur, the vaccine and
other measures can be rolled out quickly to prevent the spread of the disease.
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